Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Unipharma CoROCO:6621 -0.45%72 Days Inventory is 265.67 as of Dec. 2025, which is 27% above its 10-year median of 209.30. GuruFocus rates ROCO:6621 with a GF Score™ of 72/100 and a GF Value™ of NT$11.53 (Fairly Valued). The stock has 2 warning signs investors should review. Among 923 Drug Manufacturers companies, Unipharma Co ranks worse than 73.67% on this metric.
Days Inventory is also known as Days Sales of Inventory (DSI). Unipharma Co's Average Total Inventories for the
six
months ended in Dec. 2025 was NT$29.52 Mil. Unipharma Co's Cost of Goods Sold for the
six
months ended in Dec. 2025 was NT$20.28 Mil.
Hence, Unipharma Co's Days Inventory for the
six
months ended in Dec. 2025 was 265.67.
The historical rank and industry rank for Unipharma Co's Days Inventory or its related term are showing as below:
ROCO:6621'
s Days Inventory Range Over the Past 10 Years
Min: 115.5 Med: 209.3 Max: 244.06
Current: 240.01
During the past 13 years, Unipharma Co's highest Days Inventory was 244.06. The lowest was 115.50. And the median was 209.30.
ROCO:6621's Days Inventory is ranked worse than 73.67% of 923
companies
in the Drug Manufacturers industry
Industry Median: 164.87
vs ROCO:6621: 240.01
Unipharma Co's Days Inventory
increased
from Dec. 2024 (189.96) to Dec. 2025 (265.67).
It might indicate that Unipharma Co's sales slowed down.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Unipharma Co's Inventory Turnover for the
six
months ended in Dec. 2025 was 0.69.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Unipharma Co's Inventory-to-Revenue for the
six
months ended in Dec. 2025 was 0.67.
Unipharma Co (ROCO:6621) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
Unipharma Co's Inventory Turnover for the
six
months ended in Dec. 2025 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Unipharma Co's Inventory to Revenue for the
six
months ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
Unipharma Co Days Inventory Related Terms
Unipharma Co Days Inventory Historical Data
* Premium members only.
The historical data trend for Unipharma Co's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Unipharma Co's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Unipharma Co Days Inventory vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Unipharma Co's Days Inventory distribution charts can be found below:
* The bar in red indicates where Unipharma Co's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Unipharma Co (ROCO:6621) has a Days Inventory of 265.67 as of Dec. 2025. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Unipharma Co and its competitors. This is 27% above median its historical median of 209.30. Over the past decade, Unipharma Co's Days Inventory has ranged from 115.50 to 244.06. According to the industry distribution chart, Unipharma Co ranks #680 out of 923 companies in the Drug Manufacturers industry, placing it in the top 73.7%.
Is Unipharma Co's Days Inventory too high?
Unipharma Co's current Days Inventory of 265.67 is 27% above median its 10-year median of 209.30. Over the past 10 years, this metric has ranged from a low of 115.50 to a high of 244.06. The Drug Manufacturers industry median Days Inventory is 164.87. Unipharma Co's value of 265.67 is 61.1% above this industry median. Based on the distribution chart, Unipharma Co ranks #680 out of 923 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Unipharma Co has a GF Score™ of 72/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Unipharma Co's Days Inventory compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Unipharma Co ranks #680 out of 923 companies for Days Inventory. This places Unipharma Co in the lower half of its industry. The industry median Days Inventory is 164.87. Unipharma Co's value of 265.67 is 61.1% above this benchmark. Historically, Unipharma Co's own Days Inventory has ranged from 115.50 to 244.06 over the past decade. While the company's 10-year median is 209.30 vs. the industry median of 164.87, Unipharma Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Drug Manufacturers company?
The median Days Inventory among Drug Manufacturers companies is 164.87, based on 923 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Unipharma Co's current Days Inventory of 265.67 is 61.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Unipharma Co and its competitors. For the Drug Manufacturers industry, the median Days Inventory is 164.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Unipharma Co's current Days Inventory is 265.67, which is 27% above median its own 10-year median of 209.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Unipharma Co stock overvalued right now?
Based on GuruFocus' analysis, Unipharma Co (ROCO:6621) is currently considered Fairly Valued. The stock's GF Value™ is NT$11.53, compared to a current price of NT$11.00 — trading 4.6% below its estimated fair value. The current Days Inventory is 265.67, which is 27% above median its 10-year median of 209.30 and 61.1% above the Drug Manufacturers industry median of 164.87. Unipharma Co's overall GF Score™ is 72/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For Unipharma Co (ROCO:6621), the current Days Inventory is 265.67 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Unipharma Co (ROCO:6621) Overvalued in 2026?
Based on GuruFocus' analysis, Unipharma Co stock appears to be undervalued.
The current stock price of NT$11.00 is trading 4.6% below its estimated GF Value™ of NT$11.53.
GuruFocus considers Unipharma Co to be Fairly Valued.
Key valuation signals for ROCO:6621:
Days Inventory: 265.67 (27% above median its 10-year median of 209.30)
GF Value™: NT$11.53 vs. price of NT$11.00 (4.6% below fair value)
Industry Position: 61.1% above the Drug Manufacturers median (#680 of 923)
No single metric tells the full story. See the ROCO:6621 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Unipharma Co Ltd is a medical diagnostic, pharmaceutical and medical device company. It is engaged in developing drug products and medical equipment. The company's products offerings include Baxter, Tambocor tablets, Bain Injection, Esmolol HCL Injection, Naloxone Injection, and SAM Pelvic Sling medical device. Its customers are major medical centers, regional hospitals, regional hospitals, and clinics.
72GF Score
Get the complete analysis for ROCO:6621
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6621 has been successfully added to your 
